Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Other Non Operating Income: 2014-2024

Historic Other Non Operating Income for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to -$20.7 million.

  • Spyre Therapeutics' Other Non Operating Income rose 314.48% to $40.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.1 million, marking a year-over-year increase of 199.64%. This contributed to the annual value of -$20.7 million for FY2024, which is 8.27% down from last year.
  • According to the latest figures from FY2024, Spyre Therapeutics' Other Non Operating Income is -$20.7 million, which was down 8.27% from -$19.1 million recorded in FY2023.
  • In the past 5 years, Spyre Therapeutics' Other Non Operating Income registered a high of -$5,000 during FY2020, and its lowest value of -$20.7 million during FY2024.
  • Moreover, its 3-year median value for Other Non Operating Income was -$19.1 million (2023), whereas its average is -$13.3 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Other Non Operating Income skyrocketed by 94.26% in 2022, and later tumbled by 273,185.71% in 2023.
  • Yearly analysis of 5 years shows Spyre Therapeutics' Other Non Operating Income stood at -$5,000 in 2020, then crashed by 2,340.00% to -$122,000 in 2021, then soared by 94.26% to -$7,000 in 2022, then slumped by 273,185.71% to -$19.1 million in 2023, then declined by 8.27% to -$20.7 million in 2024.